Case Report|Articles in Press

Super acute-onset disseminated BCG infection: A case report


      Intravesical Bacillus Calmette-Guérin (BCG) instillation is an established immunotherapy for superficial bladder cancer. Herein, we describe a case of disseminated BCG infection that developed immediately after the first BCG injection. A 76-year-old man diagnosed with non-invasive bladder cancer underwent intravesical BCG instillation; he developed high fever and systemic arthralgia later that night. General examination did not reveal any infectious sources, and a combination therapy of isoniazid, rifabutin, and ethambutol was initiated after collecting his blood, urine, bone marrow, and liver biopsy samples for mycobacterial cultures. Three weeks later, Mycobacterium bovis was detected in the urine and bone marrow samples, and pathological investigation of liver biopsy revealed multiple small epithelial granulomas with focal multinucleated giant cells, leading to a diagnosis of disseminated BCG infection. The patient recovered after long-term antimycobacterial therapy without remarkable sequelae. Most cases of disseminated BCG infection occur after several doses of BCG injections, and its onset reportedly varies among cases, ranging from a few days to several months. The present case was notable as disease onset was observed only a few hours after the first BCG injection. Although rare, development of disseminated BCG infection should be considered as a differential diagnosis in patients at any time after intravesical BCG instillation therapy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Infection and Chemotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kawai K.
        • Miyazaki J.
        • Joraku A.
        • Nishiyama H.
        • Akaza H.
        Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.
        Cancer Sci. 2013; 104: 22-27
      1. Yamazaki-Nakashimada MA, Unzueta A, Berenise Gámez-González L, González-Saldaña N, Sorensen RU. BCG: a vaccine with multiple faces. Hum Vaccines Immunother. 20202;16:1841-1850. doi: 10.1080/21645515.2019.1706930.

        • Unda-Urzaiz M.
        • Cozar-Olmos J.M.
        • Miñana-Lopez B.
        • Camarero-Jimenez J.
        • Brugarolas-Rossello X.
        • Zubiaur-Libano C.
        • et al.
        En representación del Grupo Español del Registro de Cepas de BCG. Safety and efficacy of various strains of bacille Calmette-Guérin in the treatment of bladder tumours in standard clinical practice.
        Actas Urol Esp. 2018; 42: 238-248
        • Alexandroff A.B.
        • Jackson A.M.
        • O'Donnell M.A.
        • James K.
        BCG immunotherapy of bladder cancer: 20 years on.
        Lancet. 1999; 353: 1689-1694
        • Redelman-Sidi G.
        • Glickman M.S.
        • Bochner B.H.
        The mechanism of action of BCG therapy for bladder cancer–a current perspective.
        Nat Rev Urol. 2014; 11: 153-162
        • Oshima K.
        • Okabe H.
        • Tamura H.
        Results of post-marketing surveillance of immunobladder intravesical [Freeze-dried BCG intravesical (Japan)]-Drug use results survey-.
        Nippon Hinyokika Gakkai Zasshi. 2006; 19 ([in Japanese)]): 1409-1420
        • Pérez-Jacoiste Asín M.A.
        • Fernández-Ruiz M.
        • López-Medrano F.
        • Lumbreras C.
        • Tejido Á.
        • San Juan R.
        • et al.
        Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.
        Medicine (Baltim). 2014; 93: 236-254
        • Morokuma Y.
        • Uchida Y.
        • Karashima T.
        • Fujise M.
        • Imamura S.
        • Kayamori Y.
        • et al.
        Identification of Mycobacterium tuberculosis complex strains in kyushu university hospital.
        Nihon Rinsho Biseibutsu Gakkai Zasshi. 2008; 18 ([Japanese)]): 177-183
        • Huard R.C.
        • Lazzarini L.C.
        • Butler W.R.
        • van Soolingen D.
        • Ho J.L.
        PCR-based method to differentiate the subspecies of the Mycobacterium tuberculosis complex on the basis of genomic deletions.
        J Clin Microbiol. 2003; 41: 1637-1650
        • Shimizu G.
        • Amano R.
        • Nakamura I.
        • Wada A.
        • Kitagawa M.
        • Toru S.
        Disseminated Bacillus Calmette-Guérin (BCG) infection and acute exacerbation of interstitial pneumonitis: an autopsy case report and literature review.
        BMC Infect Dis. 2020; 20: 708
        • Dominguez M.L.
        • Ortiz A.
        • Rayo J.I.
        • Serrano J.
        • Infante J.R.
        • Garcia L.
        • et al.
        Utility of 67Ga scintigraphy in disseminated infection after BCG instillation for treatment of bladder carcinoma.
        Clin Nucl Med. 2013; 38: 658-660
        • Eso Y.
        • Mishima M.
        • Arasawa S.
        • Nakamura F.
        • Takeda H.
        • Takai A.
        • et al.
        Two cases of granulomatous hepatitis due to disseminated bacillus Calmette-Guérin (BCG) disease.
        Kanzo. 2017; 58: 406-414